Want to see QNRX full AI Analyst Report?
Total Valuation
Quoin Pharmaceuticals has a market cap or net worth of $8.98M. The enterprise value is $6.15M.
Market Cap$8.98M
Enterprise Value$6.15M
Share Statistics
Quoin Pharmaceuticals has 2,008,418 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,008,418
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Quoin Pharmaceuticals’s return on equity (ROE) is -1.20 and return on invested capital (ROIC) is -109.75%.
Return on Equity (ROE)-1.20
Return on Assets (ROA)-0.78
Return on Invested Capital (ROIC)-109.75%
Return on Capital Employed (ROCE)-1.10
Revenue Per Employee0.00
Profits Per Employee-5.31M
Employee Count3
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Quoin Pharmaceuticals is ―. Quoin Pharmaceuticals’s PEG ratio is 0.02.
PE Ratio―
PS Ratio0.00
PB Ratio1.65
Price to Fair Value1.65
Price to FCF-1.60
Price to Operating Cash Flow-0.82
PEG Ratio0.02
Income Statement
In the last 12 months, Quoin Pharmaceuticals had revenue of 0.00 and earned -15.80M in profits. Earnings per share was -10.63.
Revenue0.00
Gross Profit0.00
Operating Income-16.29M
Pretax Income-15.80M
Net Income-15.80M
EBITDA-15.70M
Earnings Per Share (EPS)-10.63
Cash Flow
In the last 12 months, operating cash flow was -15.86M and capital expenditures 4.00, giving a free cash flow of -15.86M billion.
Operating Cash Flow-15.86M
Free Cash Flow-15.86M
Free Cash Flow per Share-7.90
Dividends & Yields
Quoin Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.87
52-Week Price Change-48.42%
50-Day Moving Average5.13
200-Day Moving Average9.25
Relative Strength Index (RSI)48.58
Average Volume (3m)629.04K
Important Dates
Quoin Pharmaceuticals upcoming earnings date is Aug 6, 2026, Before Open (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
Quoin Pharmaceuticals as a current ratio of 3.61, with Debt / Equity ratio of 0.00%
Current Ratio3.61
Quick Ratio3.61
Debt to Market Cap0.00
Net Debt to EBITDA243.12
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Quoin Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Quoin Pharmaceuticals EV to EBITDA ratio is 241.74, with an EV/FCF ratio of 280.37.
EV to Sales0.00
EV to EBITDA241.74
EV to Free Cash Flow280.37
EV to Operating Cash Flow280.37
Balance Sheet
Quoin Pharmaceuticals has $3.12M in cash and marketable securities with $0.00 in debt, giving a net cash position of $3.12M billion.
Cash & Marketable Securities$3.12M
Total Debt$0.00
Net Cash$3.12M
Net Cash Per Share$1.56
Tangible Book Value Per Share-$247.09
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Quoin Pharmaceuticals is $23.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$23.25
Price Target Upside98.38% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast86.17%